LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN.UK

13,948

-0.41%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN.UK

13,948

-0.41%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN.UK

13,948

-0.41%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN.UK

13,948

-0.41%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN.UK

13,948

-0.41%↓

Home・Aandelen Lijst・AstraZeneca PLC

AstraZeneca PLC

Gesloten

SectorGezondheidszorg

187.14 -0.06

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

186.41

Max

188.52

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6B 3.9B
Verkoop	-215M 15B
K/W Sectorgemiddelde	28.167 49.701
EPS	1.29
Dividendrendement	1.69
Winstmarge	25.602
Werknemers	96,100
EBITDA	1.1B 5.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+15.94% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.69% 2.39%
Volgende Winsten	27 jul 2026
Volgende Ex Dividend datum	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-639M 290B
Vorige openingsprijs	187.2
Vorige sluitingsprijs	187.14

Nieuwssentiment

By Acuity

41%

59%

126 / 344 Rangschikking in Healthcare

AstraZeneca PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 16:28 UTC

Winsten

Correction to AstraZeneca Update

29 apr 2026, 15:11 UTC

Winsten

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 apr 2026, 06:31 UTC

Winsten

AstraZeneca Gets Revenue Boost From Cancer Drugs

21 mei 2026, 11:06 UTC

Marktinformatie

AstraZeneca Set for Busy End of Year -- Market Talk

13 mei 2026, 12:29 UTC

Marktinformatie

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 mei 2026, 11:54 UTC

Marktinformatie

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 mei 2026, 09:31 UTC

Marktinformatie

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 apr 2026, 10:29 UTC

Marktinformatie

Winsten

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 apr 2026, 10:06 UTC

Marktinformatie

Winsten

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 apr 2026, 09:53 UTC

Marktinformatie

Winsten

AstraZeneca Seems in Fine Health -- Market Talk

29 apr 2026, 06:05 UTC

Winsten

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 apr 2026, 06:04 UTC

Winsten

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 apr 2026, 06:04 UTC

Winsten

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 apr 2026, 06:03 UTC

Winsten

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 apr 2026, 06:03 UTC

Winsten

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 apr 2026, 06:02 UTC

Winsten

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 apr 2026, 06:01 UTC

Winsten

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 apr 2026, 06:01 UTC

Winsten

AstraZeneca Backs 2026 View

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Adj EPS $2.58

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Rev $15.29B

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Oper Pft $4.25B

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Net Pft $3.08B

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q EPS $1.97

27 apr 2026, 10:48 UTC

Marktinformatie

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 apr 2026, 11:57 UTC

Marktinformatie

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 apr 2026, 10:26 UTC

Marktinformatie

Winsten

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 apr 2026, 09:16 UTC

Marktinformatie

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 mrt 2026, 10:40 UTC

Marktinformatie

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 mrt 2026, 10:17 UTC

Marktinformatie

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Peer Vergelijking

Prijswijziging

AstraZeneca PLC Prognose

Koersdoel

By TipRanks

15.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 216.835 USD 15.94%

Hoogste 250.865 USD

Laagste 152.407 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan AstraZeneca PLC - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

126 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.